Phase I Study to Evaluate Safety and Anti-tumor Activity of PB101, an Anti-angiogenic Immunomodulating Agent
Clinical trial NCT06075849 · UNKNOWN
Trial details
- NCT number
- NCT06075849
- Sponsor
- Panolos Bioscience
- Status
- UNKNOWN
- Phase
- Phase 1
- Study type
- INTERVENTIONAL
- Start date
- 2023-10-25
- Primary completion
- 2024-10-01
- Enrollment
- 30
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.